Indications for use:
Indications for injection and tablet forms (the tablet form is prescribed after infusion): therapy and prevention of neurological ischemic disorders, which are triggered by cerebral vasospasm, subarachnoid hemorrhages due to rupture of aneurysms. Also applied during the period after surgery for subarachnoid hemorrhage.
Indications for the appointment of tablets: memory impairment, attention concentration disorders, psychoemotional lability in the elderly with severe cerebral disorders.
Pharmacological action of Nimotop:
The active substance of Nimotop is nimodipine (derivative of 1,4-dihydropyridine). The drug belongs to the group of slow calcium channel blockers. Has against ischemic and vasodilating on the vessels of the brain action. Prevent or cures spasm of cerebral vessels caused by various substances with a vasoactive effect (prostaglandins, histamine and serotonin). lipophilic drug well adheres through blood-brain and placental barriers. Has psycho- and neurotropic effects. Increases stability and improves neuronal function. Buy Nimotop on our site in any amount, it has a nootropic effect due to selective blockade of calcium channels of the cerebral cortex and hippocampus. The same molecular mechanism of action determines the vasodilating property of the product. Nimotop has no effect on atrioventricular conduction, the ability of the myocardium to contract. When taking nimodipine, there is a reflex increase in the heart rate in response to vasodilation.
When administered to patients with acute circulatory disorders of the brain, increases the blood supply parameters due to vasodilation. Additional perfusion due to vasodilatation is most pronounced in places that have insufficient blood supply, as well as damaged ones. Nimotop administration leads to a significant reduction in the risk of post-hemorrhagic ischemic neurological disorders (after subarachnoid hemorrhages), and also reduces the mortality of such patients. By purchasing from us on the website you acquire the original parser.
Due to the action on receptors of blood vessels, it has a protective effect on neurons. Increases the ability to transfer ischemic factors to nerve cells, and “syndrome of stealing” does not cause.
With memory impairment and attention disorders in people with impaired brain function, it has a positive effect – the indicators of psychometric testing, personal and behavioral responses improve.
After internal application, the active ingredient of Nimotop is almost completely absorbed from the digestive tract. Primary metabolites and nimodipine are detected in blood plasma after 10-15 minutes. With multiple use inside, the highest concentration in the blood of elderly patients is determined in 0.6-1.6 hours and is 7.3-43.2 mg / ml (with a dose of 30 mg 3 r / day). In young patients, after a single dose of 30 or 60 mg of Nimotop, the maximum concentration of the product in the blood plasma is, respectively, 16 ± 8 and 31 ± 12 mg / ml. AUC and the highest concentration of the product in the blood plasma have a dose-dependent relationship. At the first pass through the hepatic, absolute bioavailability is 5-15% due to the expressed metabolism. As a result of prolonged infusion of the product at a rate of 0.03 mg / kg / h, the stable mean concentration of nimodipine is 17.6-26.6 mg / ml. With bolus administration, a two-phase decrease in Nimotop concentration in blood plasma is observed intravenously: the first decrease in 5-10 minutes, the second in 1 hour. The product distribution volume is 0.9-1.6 l / kg, Clt (total ground clearance) is 0.6-1.9 l / h / kg.
It is connected with blood proteins 97-99% of nimodipine. In nursing mothers, the milk content of metabolites and the active substance of the product is significantly higher than the plasma concentration.
In liquor, as a consequence of internal application, the Nimotop concentration is 0.5% of the plasma one.
Up to three metabolites are transfigured that do not have clinically significant activity. Metabolism is carried out by oxidative cleavage of esters and dehydrogenation of dihydropyridine ring.
It is eliminated with urine (50%) and bile (30%) in the form of metabolites. The initial phase of the elimination half-life is 1.1-1.7 hours, the final phase is 5-10 hours.
The effect of the product on hepatic functions has not been studied. There is an increase in the bioavailability of the Nimotop in patients with impaired hepatic function due to a decrease in the intensity of the primary metabolism. Because of it, this side effect, like lowering blood pressure, may increase. In these cases, the dosage of the Nimotop is corrected depending on the hypotension. Sometimes you need to cancel the drug Nimotop.
Nimotop way of administration and dose:
Tablets should be taken orally, with a small amount of water. Do not chew. The drug is taken regardless of food. Intervals between receptions are not less than 4 hours. It is necessary to strictly follow the prescribed dosing regimen of Nimotop.